SLC5A2 and heart failure: Looking at the overall evidence available, and the broader or long-term cost-effectiveness of a treatment option like dapagliflozin, it appears that the time has come to implement the recommendations of considering SGLT-2 inhibitors as the early and preferred therapeutic option for the primary prevention of events like heart failure hospitalization and secondary prevention of CVD in patients with T2DM with high-risk factors.